Search Results - "Kaspers, G. J."

Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature by PosthumaDeBoer, J., Witlox, M. A., Kaspers, G. J. L., van Royen, B. J.

“…Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a…”
Get full text

The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia by Steur, L. M. H., Kaspers, G. J. L., van Someren, E. J. W., van Eijkelenburg, N. K. A., van der Sluis, I. M., Dors, N., van den Bos, C., Tissing, W. J. E., Grootenhuis, M. A., van Litsenburg, R. R. L.

“…Purpose To assess the impact of maintenance therapy and the additional impact of dexamethasone treatment on cancer-related fatigue and sleep-wake rhythms in…”
Get full text

Measuring vincristine-induced peripheral neuropathy in children with cancer: validation of the Dutch pediatric–modified Total Neuropathy Score by Schouten, S. M., van de Velde, M. E., Kaspers, G. J. L., Mokkink, L. B., van der Sluis, I. M., van den Bos, C., Hartman, A., Abbink, F. C. H., van den Berg, M. H.

“…Purpose The aims were to evaluate the construct validity and reliability of the Dutch version of the pediatric-modified Total Neuropathy Score (ped-mTNS) for…”
Get full text

Abandonment of childhood cancer treatment in Western Kenya by Njuguna, F, Mostert, S, Slot, A, Langat, S, Skiles, J, Sitaresmi, M N, van de Ven, P M, Musimbi, J, Muliro, H, Vreeman, R C, Kaspers, G J L

“…Background The most important reason for childhood cancer treatment failure in low-income countries is treatment abandonment. Objective The aim of this study…”
Get full text

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia by Marke, R, Havinga, J, Cloos, J, Demkes, M, Poelmans, G, Yuniati, L, van Ingen Schenau, D, Sonneveld, E, Waanders, E, Pieters, R, Kuiper, R P, Hoogerbrugge, P M, Kaspers, G J L, van Leeuwen, F N, Scheijen, B

Get full text

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse by Bachas, C, Schuurhuis, G J, Assaraf, Y G, Kwidama, Z J, Kelder, A, Wouters, F, Snel, A N, Kaspers, G J L, Cloos, J

“…The majority of pediatric and younger adult (<60 years) AML patients achieve complete remission. However, 30–40% of patients relapse and display a dismal…”
Get full text

Influence of health insurance status on childhood cancer treatment outcomes in Kenya by Olbara, Gilbert, Martijn, H. A., Njuguna, F., Langat, S., Martin, S., Skiles, J., Vik, T., Kaspers, G. J. L., Mostert, S.

“…Background Survival of childhood cancer in high-income countries is approximately 80%, whereas in low-income countries, it is less than 10%. Limited access to…”
Get full text

Psychometric properties and norm scores of the sleep self report in Dutch children by Steur, L M H, Grootenhuis, M A, Terwee, C B, Pillen, S, Wolters, N G J, Kaspers, G J L, van Litsenburg, R R L

“…Psychometrically robust questionnaires to assess self-reported sleep problems in children are important since sleep problems can have a major impact on child…”
Get full text

Parental experiences of childhood cancer treatment in Kenya by Njuguna, F., Mostert, S., Seijffert, A., Musimbi, J., Langat, S., van der Burgt, R. H. M., Skiles, J., Sitaresmi, M. N., van de Ven, P. M., Kaspers, G. J. L.

“…Purpose Our study explores socioeconomic, treatment-related, and psychological experiences of parents during cancer treatment of their children at an academic…”
Get full text

Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases by van den Berg, M.H., van Dulmen-den Broeder, E., Overbeek, A., Twisk, J.W.R., Schats, R., van Leeuwen, F.E., Kaspers, G.J., Lambalk, C.B.

“…OBJECTIVE The aim of this study was to evaluate whether values of FSH, LH, estradiol, anti-Müllerian hormone (AMH), inhibin B, antral follicle count (AFC) and…”
Get full text

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples by CLOOS, J, GOEMANS, B. F, CREUTZIG, U, SCHUURHUIS, G. J, ZWAAN, Ch. M, KASPERS, G. J. L, HESS, C. J, VAN OOSTVEEN, J. W, WAISFISZ, Q, CORTHALS, S, DE LANGE, D, BOECKX, N, HÄHLEN, K, REINHARDT, D

“…In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis. We determined FLT3 internal tandem…”
Get full text

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML by Hollink, I H I M, Zwaan, C M, Zimmermann, M, Arentsen-Peters, T C J M, Pieters, R, Cloos, J, Kaspers, G J L, de Graaf, S S N, Harbott, J, Creutzig, U, Reinhardt, D, van den Heuvel-Eibrink, M M, Thiede, C

“…Nucleophosmin ( NPM1 ) mutations occur frequently in adult cytogenetically normal acute myeloid leukemia (CN-AML) and confer favorable outcome. We investigated…”
Get full text

Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma by Drechsel, K. C. E., Broer, S. L., Stoutjesdijk, F. S., Twisk, J. W. R., van den Berg, M. H., Lambalk, C. B., van Leeuwen, F. E., Overbeek, A., van den Heuvel-Eibrink, M. M., van Dorp, W., de Vries, A. C. H., Loonen, J. J., van der Pal, H. J., Kremer, L. C., Tissing, W. J., Versluys, B., Kaspers, G. J. L., van Dulmen-den Broeder, E., Veening, M. A.

“…Purpose To evaluate the impact of treatment for Hodgkin lymphoma (HL) on clinical reproductive markers and pregnancy outcomes. Methods This study was embedded…”
Get full text

Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study by van Dijk, M., van Leeuwen, F. E., Overbeek, A., Lambalk, C. B., van den Heuvel-Eibrink, M. M., van Dorp, W., Tissing, W. J., Kremer, L. C., Loonen, J. J., Versluys, B., Bresters, D., Ronckers, C. M., van der Pal, H. J., Beerendonk, C. C. M., Kaspers, G. J. L., van Dulmen-den Broeder, E., van den Berg, M. H.

“…Purpose To evaluate pregnancy rates, time to pregnancy (TTP) and obstetric outcomes in female childhood cancer survivors (CCSs) and to identify specific…”
Get full text

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia by GOEMANS, B. F, ZWAAN, Ch. M, KASPERS, G. J. L, HEINRICH, M. C, MILLER, M, ZIMMERMANN, M, HARLOW, A, MESHINCHI, S, LOONEN, A. H, HIHLEN, K, REINHARDT, D, CREUTZIG, U

“…Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the…”
Get full text

The volume effect in paediatric oncology: a systematic review by Knops, R.R.G., van Dalen, E.C., Mulder, R.L., Leclercq, E., Knijnenburg, S.L., Kaspers, G.J.L., Pieters, R., Caron, H.N., Kremer, L.C.M.

“…For several adult cancer types, there is evidence that treatment in high volume hospitals, high case volume providers, or in specialised hospitals leads to a…”
Get full text

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery by PosthumaDeBoer, J, Piersma, S R, Pham, T V, van Egmond, P W, Knol, J C, Cleton-Jansen, A M, van Geer, M A, van Beusechem, V W, Kaspers, G J L, van Royen, B J, Jiménez, C R, Helder, M N

“…Background: Osteosarcoma (OS) is the most common bone tumour in children and adolescents. Despite aggressive therapy regimens, treatment outcomes are…”
Get full text

Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia by Parigger, J., Zwaan, C. M., Reinhardt, D., Kaspers, G. J. L.

“…Gemtuzumab ozogamicin, an anti-tumour antibiotic linked to an anti-CD33 antibody (Mylotarg®), has been well studied in AML in adults but to a lesser extent in…”
Get full text

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation by Marshall, G M, Dalla Pozza, L, Sutton, R, Ng, A, de Groot-Kruseman, H A, van der Velden, V H, Venn, N C, van den Berg, H, de Bont, E S J M, Maarten Egeler, R, Hoogerbrugge, P M, Kaspers, G J L, Bierings, M B, van der Schoot, E, van Dongen, J, Law, T, Cross, S, Mueller, H, de Haas, V, Haber, M, Révész, T, Alvaro, F, Suppiah, R, Norris, M D, Pieters, R

“…Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In…”
Get full text

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells by Franke, N E, Niewerth, D, Assaraf, Y G, van Meerloo, J, Vojtekova, K, van Zantwijk, C H, Zweegman, S, Chan, E T, Kirk, C J, Geerke, D P, Schimmer, A D, Kaspers, G J L, Jansen, G, Cloos, J

“…Proteasome inhibition is a novel treatment for several hematological malignancies. However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is…”
Get full text